The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2016 | Should we use the word ‘cure’ in CLL?
Peter Hillmen, MBChb, PhD, FRCP, FRCPath from St. James’ University Hospital, Leeds, UK discusses the use of the word ‘cure’ in chronic lymphocytic leukemia (CLL). According to Prof. Hillmen, the word ‘cure’ is not used frequently, instead physicians talks about ‘control’ and ‘treatment-free intervals’. The aim is to move towards a cure. With combinations of novel agents and chemotherapy, deep remissions are seen in patients, and this work may lead to a cure according to Prof. Hillmen.
Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.
